Status:
COMPLETED
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Parkinson's Disease
Psychoses
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
Eligibility Criteria
Inclusion
- Primary diagnosis of idiopathic Parkinson's disease.
- Psychosis related to Parkinson's disease.
Exclusion
- Psychosis present prior to diagnosis of Parkinson's disease.
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00095810
Start Date
July 1 2003
End Date
September 1 2004
Last Update
November 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Albany, New York, United States